Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV infection and set a date of June 19 to decide on its approval, Gilead ...